Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-100
SponsorNorthwestern University
About this trial
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
Eligibility criteria
Qualifiers
Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)
Disqualifiers
Patients who lack decisional capacity
Patients unable to read/speak English
Patients who are on a blood thinner (anticoagulation medication)
Patients who do not have internet access to complete postoperative surveys
Trial design
Treatments tested in this trial
- Magneto 150 holmium laser
- Moses 2.0 holmium laser
Treatment groups
180 Participants
are divided into 2 treatment groupsSponsors and collaborators
Northwestern University
Lead sponsor
Cook Group Incorporated
Collaborator
Source ClinicalTrials.gov